Algocyte gives payors and value-based care organisations a longitudinal oncology monitoring layer that reduces avoidable admissions and total cost of care.
Episodic monitoring lets complications surface only after clinical deterioration.
Claims-based risk management sees the bill, not the biology.
Acute-care interventions cost orders of magnitude more than early intervention.
Clinical signal is split across providers and systems.
At-home CBC testing on Algocyte Proxima, AI risk stratification and remote escalation surface haematological toxicity early, directly reducing ED utilisation and avoidable admissions.
Meet Proxima
Population-level risk stratification across oncology cohorts plugs into existing care management workflows, and gives shared-risk contracts a regular, structured signal.
Inside Health HubWe co-select the oncology population where impact is most measurable.
Devices ship to members; onboarding is fully remote.
AI risk scoring across longitudinal CBC and symptom data.
Quarterly review against avoided admissions and contracted endpoints.
Personal health intelligence, in one place you control.
Learn moreNHS oncology programs and dashboards with EHR integration in development.
Learn moreSponsor-supported oncology and decentralized trials.
Learn moreClozapine monitoring in the community.
Learn moreBook a 20-minute briefing with our clinical team to see Algocyte in action.